Sign inJoin waitlistJoin the waitlist

Benjamin Tomlinson

Program Director, Hematology and Oncology, UH Cleveland Medical Center · Case Western Reserve University/University Hospitals Cleveland Medical Center

Credentials: · · · ·

History

Hematology and Oncology, UH Cleveland Medical Center · Case Western Reserve University/University Hospitals Cleveland Medical Center
Present
Case Western Reserve University/University Hospitals Cleveland Medical Center
Present
Case Western Reserve University/University Hospitals Cleveland Medical Center
Present

University Of California At Davis Comprehensive Cancer Center
2012–2015
Internal Medicine
University of California (Davis) Medical Center
2009–2012
Case Western Reserve University School of Medicine
2005–2009
Case Western Reserve University
2001–2005

Research

Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network
Leukemia · 2021 · 91 citations
Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2018 · 88 citations
Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors
Clinical Cancer Research · 2015 · First of 14 authors · 75 citations

Marcos de Lima
22 papers
Brenda Cooper
21 papers
Leland Metheny
19 papers
Paolo Caimi
19 papers
Hillard Lazarus
15 papers
Folashade Otegbeye
14 papers · 1 as a fellow
Ehsan Malek
13 papers
Molly Gallogly
13 papers
KB
Kirsten Boughan
9 papers
Erika Moore
4 papers
Jiasheng Wang
4 papers · 4 as a fellow
Koen van Besien
4 papers

Clinical trials

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Principal investigator · Recruiting · Phase 1, Phase 2
Benjamin Tomlinson
2025–2027
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Principal investigator · Suspended · Phase 1
David Wald
2022–2027
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Principal investigator · Active not recruiting · Phase 1
Benjamin Tomlinson
2021–2040
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Principal investigator · Recruiting · Early phase 1
Benjamin Tomlinson
2020–2027